Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03301636
Title A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors NewLink Genetics Corporation
Indications

melanoma

Therapies

Indoximod + Nivolumab

Indoximod + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST